References
- Shimizu Y, Yamamoto M, Naishiro Y, Sudoh G, Ishigami K, Yajima H, et al. Necessity of early intervention for IgG4-related disease – delayed treatment induces fibrosis progression. Rheumatology (Oxford). 2013;52(4):679–83.
- Yamamoto M, Takahashi H, Shinomura Y. Mechanisms and assessment of IgG4-related disease: lessons for the rheumatologist. Nat Rev Rheumatol. 2014;10(3):148–59.
- Tabata T, Kamisawa T, Takuma K, Egawa N, Setoguchi K, Tsuruta K, et al. Serial changes of elevated serum IgG4 levels in IgG4-related systemic disease. Intern Med. 2011;50(2):69–75.
- Masaki Y, Dong L, Kurose N, Kitagawa K, Morikawa Y, Yamamoto M, et al. Proposal for a new clinical entity, IgG4-positive multi-organ lymphoproliferative syndrome: Analysis of 64 cases of IgG4-related disorders. Ann Rheum Dis. 2009;68(8):1310–5.
- Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol. 2012;22(1):21–30.
- Aalberse RC, Stapel SO, Schuurman J, Rispens T. Immunoglobulin G4: an odd antibody. Clin Exp Allergy. 2009;39(4):469–77.
- Hamilton RG. Chapter 3. Human Immunoglobulin. In: Leffell MS, Donnenberg AD, Rose NR, editors. Handbook of Human Immunology, 1 ed. Boca Raton FL: CRC Press, 1997:65–110.
- Terao C, Ohnuma K, Yamamoto K, Yukawa N, Kawabata D, et al. Serum IgG levels demonstrate seasonal change in connective tissue disease: a large-scale, 4-year analysis in Japanese. Mod Rheumatol. 2012;22(3):426–30.